XClose

Centre for Amyloidosis and Acute Phase Proteins

Home
Menu

National Amyloidosis Centre

Information for patients on the coronavirus (COVID-19)


UPDATE:  As of 01 June 2020 the National Amyloidosis Centre has reopened. We will be conducting clinics via telephone/video-link, or where appropriate, in person. We will be in touch to let you know what type of appointment you will be having.

For FEVER PATIENTS who receive treatments at the Centre, such as Canakinumab, Anakinra and Tocilizumab, they will continue to have their appointments at this time.  Please contact Michael Wood or Bella Sombrito if you have any questions.

Please follow this link for information on the coronavirus (COVID-19)
 

 

Head, Centre for Amyloidosis & Acute Phase Proteins and NAC Research Lead

Professor Julian Gillmore020 7433 2737/2798
   
NAC Clinical LeadProfessor Helen Lachmann020 7433 2737/2798
   
Deputy Clinical and Research LeadProfessor Marianna Fontana020 7433 2764
   
Emeritus Professor and ConsultantProfessor Sir Mark Pepys020 7433 2801
   
Professors/ConsultantsProfessor Philip Hawkins020 7433 2737/2798
 Professor Ashutosh Wechalekar020 7433 2737/2798
   
Readers/Senior Lecturers/ConsultantsDr Dan Knight020 7433 2765
 Dr Ayesha Shameem Mahmood020 7433 2737/2798
 Dr Ana Martinez De Azcona Naharro020 7433 2777
 Dr Carol Whelan020 7433 2737/2798
 Dr Brendan Wisniowski020 7433 2789
   
Clinical Research StaffDr Liza Chacko020 7433 2777
 Dr Oliver Cohen020 7433 2733
 Dr Steven Law020 7433 2823
 Dr Rishi Patel020 7433 2777
 Dr Sriram Ravichandran020 7433 2763
 Dr Yousuf Razvi020 7433 2777
   
Lead NurseAngelique Smit020 7433 2770
   
Lead Nuclear Medicine TechnologistDavid Hutt020 7433 2742
   
Service ManagerRamon Lamarca020 7433 2756
   
Nursing Helpline 020 7433 2799/
07790 989695
   
Specialist/Research NursesDarren Foard 
 Lisa Rannigan 
 Bellaruth Sombrito 
 Svetla Strehina 
 Michael Wood 
   
Clinical Trial CoordinatorSarah Louth 
rf-tr.amyloidosisclinicalresearch@nhs.net
020 7433 2723
   
Clinical Pathway ManagerRizwan Shaukat020 7433 2732
   
Medical SecretariesCauvery Shelat / Kay Law020 7433 2737/2798
   
Appointmentsrf.amyloidosisappointments@nhs.net020 7433 2812/2725/2800
   
Blood Results (excluding genetic testing results)rf.amyloidosisresults@nhs.net020 7433 2812
   
Transport & AccommodationOnana Ayissi020 7433 2812
   
General Enquiriesrf.amyloidosisadmin@nhs.net020 7433 2811
   
Fax (for academic use only - please do not use for clinical matters) 020 7433 2817


The NHS National Amyloidosis Centre is the only centre in the UK specialising in amyloidosis and is part of University College London Centre for Amyloidosis and Acute Phase Proteins, one of the world's leading centres for amyloid research. The Centre has "state of the art" clinical and research facilities, and a team of highly qualified clinical, research and support staff.

We pioneered scintigraphic imaging (scanning) of amyloid as a quantitative diagnostic procedure and provide a comprehensive clinical service for patients with all types of acquired and hereditary systemic amyloidosis.  The NHS National Amyloidosis Centre is commissioned by NHS National Specialised Services and funded by the Department of Health to provide a diagnostic and management advice service for the UK's national caseload of patients with amyloidosis and related disorders. The clinical service includes:

    • Detailed clinical assessment.
    • Diagnosis, quantification and monitoring of amyloidosis with whole body SAP scintigraphy.
    • Comprehensive expert diagnostic and monitoring studies of the heart, as required, by cardiac magnetic resonance, echocardiography and DPD scanning.
    • Review of diagnostic biopsies and specialised immunohistochemistry to determine amyloid type.
    • Characterisation and exclusion of hereditary amyloidosis by DNA testing; genetic counselling.
    • Measurement and monitoring of specialised biochemical (blood) tests for serum free light chains and serum amyloid A protein.
    • Recommendations for treatment and monitoring response.
    • 3‑12 monthly follow‑up to assess response and further treatment requirements. Sometimes follow‑up assessment can be performed by telephone if patients live far away.
    • Providing information and support to amyloidosis patients, their families and health providers.
    • Systematic evaluation of existing and new treatments.
    • Diagnosis, monitoring and treatment of inherited fever syndromes.